The perfect AI stock under $10
Sponsored
If you're looking for a great AI stock under $10… you need to watch this right away. What the company is doing is pretty incredible. It could end up saving billions of lives… and billions of dollars. In short, the company is the creator of the first AI-designed drug to enter clinical trials. And this is a huge deal. Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. The Wall Street Journal reports that “the time required for the early stages of drug discovery could shrink from years to months.” Not only that, it has the potential to develop “never-before-seen molecules that could treat diseases like pancreatic cancer or ALS.” In short, this is groundbreaking stuff. And this #1 AI company is at the forefront of all of it. The biggest pharmaceutical companies in the world are lining up to work with them. For example…
- Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
- French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
- Bristol Meyers Squibb signed a $1.2 billion partnership with the company.
And yet… the company I'm talking about is valued at just over $500 million today. And it trades for less than $10. In other words, these deals have the potential to drive the stock many times higher in the months and years ahead. So again, if you're looking for a great AI stock to own, you need to watch this presentation right away.
P.S. The best way to play this AI stock involves an investment strategy used by a Kansas welder to become one of the wealthiest people in the world. See his incredible investment approach here.
By Jody Chudley
This year, the performance of the S&P 500 has been heavily dependent on a group of stocks known as the “Magnificent Seven.”
These are the seven giant tech stocks that have accounted for nearly all the S&P 500’s gains this year.
You know the names.
The group is composed of Apple (Nasdaq: AAPL), Amazon (Nasdaq: AMZN), Alphabet (Nasdaq: GOOGL), Meta Platforms (Nasdaq: META), Microsoft (Nasdaq: MSFT), Nvidia (Nasdaq: NVDA) and Tesla (Nasdaq: TSLA).
Just look at how these massive stocks have performed in 2023…
The worst-performing stock of the bunch is up 40%!
After a big year like this, you won’t be surprised to learn that the stocks in the Magnificent Seven are not cheap.
The average price-to-earnings ratio of these seven stocks is a gaudy 41.
That is rich… but it’s no surprise.
These stocks have carried the S&P 500 to a 14% increase so far in 2023.
However, if you remove the performance of the Magnificent Seven, the S&P 500 would be roughly flat for the year.
These big stocks have heavy weightings in the index, and as a result, their performance has a significant impact on it.
Again, the S&P 500 is up 14% in 2023… but the equal-weighted version of the index is hardly up at all.
While the strong performance of the Magnificent Seven has made those stocks (and the market cap-weighted S&P 500) expensive, the underperformance of the rest of the market has made many other stocks cheap.
The S&P MidCap 400 Index and the S&P SmallCap 600 Index are cheap on a forward price-to-earnings basis, and both indexes are very inexpensive relative to where they’ve traded this century.
Trading at 12.2 and 11.4 times forward earnings, respectively, both midcap and small cap stocks look very appealing compared with the rest of the market.
The biggest stocks, on the other hand, are not where we want to be putting our money today.
With all of this in mind, The Value Meter is going to weigh in on a few different assets this week:
The Magnificent Seven, which are trading at an average of 41 times earnings, are on the verge of being “Extremely Overvalued.” (Perhaps they’re even “Magnificently Overvalued”!)
The SPDR S&P 500 ETF Trust (NYSE: SPY), which tracks the S&P 500 and is dominated by the Magnificent Seven, is at least “Slightly Overvalued.”
The Invesco S&P 500 Equal Weight ETF (NYSE: RSP), which tracks the equal-weighted S&P 500 index and is not dominated by the Magnificent Seven, is “Slightly Undervalued.”
Both the SPDR Portfolio S&P 400 Mid Cap ETF (NYSE: SPMD) and the SPDR Portfolio S&P 600 Small Cap ETF (NYSE: SPSM) are on the verge of being “Extremely Undervalued.
Crazy Opportunity: Tiny $3 AI Stock Could Make You Rich
Sponsored
Hey, Ross Givens here. You know what Bill Gates says about AI? ”If you invent a breakthrough in artificial intelligence, so machines can learn, that is worth 10 Microsofts.” Darned right! Now that ChatGPT has ignited a firestorm in AI… Some analysts say Mr. Gates was too conservative. That the market opportunity is far, far greater than 10 Microsofts. So no matter whether you start with $50, $250, or $1,000… NOW is the time to get a piece of the action. And if you move quickly – before the mainstream press gets wind of what's going on – a tiny $3 AI Wonder Stock could jumpstart the kind of carefree life you can only dream about right now.
Getting positioned is easy… But you'll need to know its name and ticker symbol. (Which I'm prepared to give you now.) Discover more about The $3 AI Wonder Stock That Could Make You 75X Richer. And here's the great thing… I'll bet not one in 1 in 100,000 investors knows about this scorching opportunity! Just follow my steps to buy the actual stock at the real price of $3 or so. But you'll need to move extremely fast. The price could shoot way up at any time.
